Results 161 to 170 of about 90,622 (332)

Characterization of T-Cell Subpopulations in Skin and Peripheral Blood of Patients with Cutaneous T-Cell Lymphomas and Benign Inflammatory Dermatoses

, 1983
Rein Willemze, Claire B. De Graaff-Reitsma, J. Cnossen, W.A. van Vloten, Chris J.L.M. Meijer   +4 more
openalex   +1 more source

Differentiation of Human T Lymphocytes: II. Phenotypic Difference in Skin and Blood Malignant T-Cells in Cutaneous T-Cell Lymphoma

, 1982
Barton F. Haynes, Lucinda L. Hensley, Brian V. Jegasothy   +2 more
openalex   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

CD4+ cutaneous T-cell lymphomas show the phenotype of helper/inducer T cells (CD45RA-, CDw29+)

, 1989
Wolfram Sterry, Volker Mielke
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Synergistic Efficacy of Chidamide and LB100 in Sézary Syndrome via TNC Downregulation and PI3K/AKT/mTOR Dephosphorylation

Cancer Science, EarlyView.
Chidamide combined with LB100 can effectively promote the death of Sézary Syndrome by inhibiting the expression of TNC and the phosphorylation of PI3K/AKT/mTOR. ABSTRACT Primary cutaneous T‐cell lymphoma (CTCL) manifests as a distinct variant of T‐cell non‐Hodgkin's lymphoma, predominantly impacting skin tissues and constituting approximately 75%–80 ...
Nan Chen, Yuan Wang, Lan Luo, Xin Hua, Qingfeng Xue, Beiqi Gong, Yaping Zhang, Wenyu Shi   +7 more
wiley   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

Dual genotype in cutaneous T cell lymphoma: Immunoglobulin gene rearrangement in clonal T cell malignancy

, 1989
Yves‐Jean Bignon, P Souteyrand, H. Roger, David Bernard   +3 more
openalex   +1 more source

New Topical and Systemic Treatments for Atopic Dermatitis

Clinical &Experimental Allergy, EarlyView.
This review summarises new topical and systemic treatments for atopic dermatitis, their relative effectiveness, and important safety data. ABSTRACT Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing–remitting course.
Sara Mirali, Aaron M. Drucker
wiley   +1 more source

Round Cells of the Epidermis: Clues from Studies on Neoplastic Lymphocytes of Cutaneous T Cell Lymphoma

, 1980
Richard L. Edelson
openalex   +1 more source